Liposomal L-arginine 80% — High Bioavailability Nitric Oxide Support Supplement

Product Overview

liposomal L-Arginine 80% is a premium-grade dietary supplement ingredient delivering L-arginine in an advanced liposomal delivery system. L-Arginine (CAS 74-79-3), also known as (2S)-2-amino-5-(carbamimidamido)pentanoic acid, is a conditionally essential amino acid with the molecular formula C₆H₁₄N₄O₂ and a molecular weight of 174.20 g/mol. It is a white crystalline powder or crystalline substance that is freely soluble in water (148.7 g/L at 20°C), sparingly soluble in alcohol, and insoluble in ether. It is strongly alkaline, and its water solutions absorb carbon dioxide from the air.

L-Arginine is a basic amino acid containing two amino groups and one carboxyl group. The most important dietary sources of L-arginine are dairy products, meat, fish, nuts, and seeds. L-Arginine is an intermediate in the urea cycle, which is involved in eliminating ammonia from the body as non-toxic urea. In addition to being supplied via the diet, arginine can be synthesized endogenously from citrulline, a urea cycle intermediate, in the liver and kidney. Although arginine is not an essential amino acid, it is considered conditionally indispensable given that a dietary source is required only when endogenous synthesis cannot meet metabolic needs.

Why Liposomal Technology?

Conventional L-arginine presents significant formulation challenges. The compound undergoes extensive first-pass metabolism by arginase in the liver and enterocytes, with oral bioavailability measured in the range of 21–68%. Additionally, L-arginine has a short half-life, which limits its efficacy for sustained NO production.

Liposomal encapsulation provides four critical advantages:

1. Dramatically Enhanced Bioavailability — A pharmacokinetic study comparing liposome-encapsulated L-arginine with free L-arginine in pregnant rats demonstrated that encapsulation increased blood arginine exposure more than 120-fold and significantly increased plasma and placental concentrations compared to free forms.

2. Protection from First-Pass Metabolism — The phospholipid bilayer shields L-arginine from enzymatic degradation by arginase, preserving its intact structure until reaching systemic circulation. This is particularly important because arginase rapidly metabolizes L-arginine into urea and ornithine in the liver and intestine.

3. Sustained Release and Enhanced Tissue Delivery — Liposomal delivery provides a sustained-release profile that maintains steady plasma amino acid levels, supporting prolonged NO production. In a rat model of preeclampsia and fetal growth restriction, encapsulated amino acids reduced maternal blood pressure without affecting fetal weight, demonstrating effective targeted delivery.

4. Enhanced Cellular Uptake — Liposomes fuse directly with cell membranes, facilitating efficient cellular delivery via lipid-mediated pathways. The liposomal delivery system bypasses the competitive amino acid transport pathways utilized by free L-arginine, ensuring efficient delivery of the amino acid to target cells including endothelial cells.

Product Specifications

Key Features

• High Purity — Standardized to ≥80% L-arginine, with USP-grade assay of 98.5%–101.5% on dried basis available.

• Liposomal Enhancement — Phospholipid bilayer encapsulation increases blood arginine exposure more than 120-fold compared to free L-arginine in pharmacokinetic studies.

• Superior Nitric Oxide Precursor — L-Arginine is the primary substrate for eNOS and is required, together with oxygen, NADPH, and tetrahydrobiopterin, to enzymatically produce NO.

• Clinically Studied for Endothelial Function — A randomized, double-blind trial in 35 patients with essential hypertension demonstrated that 6 g of oral L-arginine significantly improved flow-mediated dilatation of the brachial artery (1.7 ± 3.4 vs. 5.9 ± 5.4%, P=0.008).

• Clinically Studied for Peripheral Artery Disease — A randomized study in 100 patients with atherosclerotic lower limb ischemia demonstrated that 6 g/day of oral L-arginine for 30 and 60 days significantly increased NO and total antioxidant status levels (p<0.001) and extended pain-free walking distance (p<0.001).

• Clinically Studied for Exercise Capacity — A study in patients with stable angina pectoris demonstrated that oral supplementation with L-arginine (6 g/day for 3 days) increases exercise capacity.

• GRAS and FDA Affirmed — L-Arginine is Generally Recognized As Safe (GRAS) by the FDA under 21 CFR 582.5145 for use as a nutrient supplement, with no limitation other than current good manufacturing practice.

• Water-Soluble — Freely soluble in water (148.7 g/L at 20°C); suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated L-arginine across a range of doses. A randomized, double-blind trial in patients with essential hypertension used 6 g of oral L-arginine to acutely improve endothelium-dependent vasodilation. A randomized study in patients with atherosclerotic lower limb ischemia used 6 g/day for 30 and 60 days. The optimal daily dose for supplementation is 3–6 g, with an Observed Safe Level (OSL) of 20 g and a No Observed Adverse Effect Level (NOAEL) of 42 g per day according to the FDA. To improve tolerability, it is recommended to divide the daily dose into multiple portions and take on an empty stomach, so that competing food proteins do not interfere with absorption. For cardiovascular support, 6 g/day is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Important Safety Information: L-Arginine is generally well tolerated. Reported side effects are mild and may include nausea, vomiting, flushing, headache, and local venous irritation, particularly with rapid intravenous infusion at large doses. Caution is advised when taking L-arginine with blood pressure medication, nitrates, or PDE5 inhibitors due to potential additive effects on blood pressure. Individuals with low blood pressure or heart-related conditions should consult a healthcare professional before use.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.